NASDAQ:RGNX - Regenxbio Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$78.80 +3.70 (+4.93 %)
(As of 07/18/2018 08:00 AM ET)
Previous Close$75.10
Today's Range$75.10 - $79.95
52-Week Range$17.60 - $85.10
Volume485,700 shs
Average Volume693,001 shs
Market Capitalization$2.40 billion
P/E Ratio-32.16
Dividend YieldN/A
Beta-1.1
Regenxbio logoREGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration. It is also developing RGX-501 for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111 to treat the neurological symptoms of Mucopolysaccharidosis Type I that uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system (CNS). In addition, the company engages in the development of RGX-121 for the treatment of neurological symptoms of Mucopolysaccharidosis Type II, which uses the AAV9 vector to deliver the human iduronate-2-sulfatase gene to the CNS. Further, it licenses its NAV technology platform to other biotechnology companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Receive RGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RGNX
CUSIPN/A
Phone240-552-8181

Debt

Debt-to-Equity RatioN/A
Current Ratio17.67
Quick Ratio17.67

Price-To-Earnings

Trailing P/E Ratio-32.16
Forward P/E Ratio25.42
P/E Growth6.1

Sales & Book Value

Annual Sales$10.39 million
Price / Sales242.24
Cash FlowN/A
Price / CashN/A
Book Value$5.88 per share
Price / Book13.40

Profitability

EPS (Most Recent Fiscal Year)($2.45)
Net Income$-73,160,000.00
Net Margins37.28%
Return on Equity23.27%
Return on Assets21.78%

Miscellaneous

Employees139
Outstanding Shares31,940,000
Market Cap$2,398.40

The Truth About Cryptocurrencies

Regenxbio (NASDAQ:RGNX) Frequently Asked Questions

What is Regenxbio's stock symbol?

Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."

How were Regenxbio's earnings last quarter?

Regenxbio Inc (NASDAQ:RGNX) issued its earnings results on Tuesday, May, 8th. The biotechnology company reported $3.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.00 by $2.04. The biotechnology company earned $132.39 million during the quarter, compared to analysts' expectations of $80 million. Regenxbio had a return on equity of 23.27% and a net margin of 37.28%. View Regenxbio's Earnings History.

When is Regenxbio's next earnings date?

Regenxbio is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Regenxbio.

What price target have analysts set for RGNX?

7 brokerages have issued twelve-month price targets for Regenxbio's shares. Their forecasts range from $25.00 to $130.00. On average, they expect Regenxbio's share price to reach $62.4286 in the next year. This suggests that the stock has a possible downside of 20.8%. View Analyst Ratings for Regenxbio.

What is the consensus analysts' recommendation for Regenxbio?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Regenxbio stock?

Here are some recent quotes from research analysts about Regenxbio stock:
  • 1. Raymond James analysts commented, "We are maintaining our Outperform rating and raising our target price to $76 (previously was $45) for REGENXBIO, primarily driven by our increasing confidence in the company’s pipeline products and the gene therapy space as a whole as well as the inclusion of the company’s wholly owned MPS programs into our models. With two wholly owned assets poised to deliver clinical data in late 2018, a powerful AAV technology platform with >20+ partnered programs (10 of which are in the clinic), and a cash position of $311 million (pro forma), we continue to recommend REGENXBIO shares to risk-tolerant investors." (6/25/2018)
  • 2. According to Zacks Investment Research, "REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland. " (4/17/2018)
  • 3. Chardan Capital analysts commented, "We have long highlighted the importance of vector science for the progress in GT; and, we see Commissioner Gottlieb’s comments as highly supportive of our views. We again highlight REGENXBIO (Buy) (a Chardan Top Pick for 2017, and our Gene Therapy Top Pick) as the best way to play the emergence of in vivo GT, due to the company’s: (1) rights to 100+ vectors, (2) partnerships with 10 companies, (3) 25 or so internal and external product candidates, over 10 of which are in clinical development, and (4) abundance of important 2017 catalysts, which to us represent upside options." (12/11/2017)

Are investors shorting Regenxbio?

Regenxbio saw a increase in short interest in the month of June. As of June 15th, there was short interest totalling 3,575,876 shares, an increase of 45.5% from the May 31st total of 2,458,301 shares. Based on an average trading volume of 1,201,842 shares, the days-to-cover ratio is presently 3.0 days. Approximately 12.8% of the company's shares are short sold. View Regenxbio's Current Options Chain.

Who are some of Regenxbio's key competitors?

Who are Regenxbio's key executives?

Regenxbio's management team includes the folowing people:
  • Mr. Kenneth T. Mills, CEO, Pres & Director (Age 43)
  • Mr. Vittal K. Vasista, Chief Financial Officer (Age 50)
  • Dr. Olivier Danos, Chief Scientific Officer (Age 60)
  • Mr. Curran M. Simpson, Sr. VP of Technical Operations (Age 56)
  • Mr. Patrick J. Christmas II, Sr. VP & Gen. Counsel (Age 47)

Has Regenxbio been receiving favorable news coverage?

News coverage about RGNX stock has been trending somewhat positive on Wednesday, according to Accern Sentiment. Accern scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Regenxbio earned a media sentiment score of 0.20 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.01 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are Regenxbio's major shareholders?

Regenxbio's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Bank of Montreal Can (0.12%), State of Alaska Department of Revenue (0.03%) and Xact Kapitalforvaltning AB (0.01%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Institutional Ownership Trends for Regenxbio.

Which institutional investors are buying Regenxbio stock?

RGNX stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can, State of Alaska Department of Revenue and Xact Kapitalforvaltning AB. View Insider Buying and Selling for Regenxbio.

How do I buy shares of Regenxbio?

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regenxbio's stock price today?

One share of RGNX stock can currently be purchased for approximately $78.80.

How big of a company is Regenxbio?

Regenxbio has a market capitalization of $2.40 billion and generates $10.39 million in revenue each year. The biotechnology company earns $-73,160,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis. Regenxbio employs 139 workers across the globe.

How can I contact Regenxbio?

Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]


MarketBeat Community Rating for Regenxbio (NASDAQ RGNX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  204 (Vote Outperform)
Underperform Votes:  147 (Vote Underperform)
Total Votes:  351
MarketBeat's community ratings are surveys of what our community members think about Regenxbio and other stocks. Vote "Outperform" if you believe RGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.